GoKawiilGillis, A. et al. Critical assessment of G protein-biased agonism at the μ-opioid receptor. Trends Pharmacol. Sci. 41, 947–959 (2020).
Varga, B. R., Streicher, J. M. & Majumdar, S. Strategies towards safer opioid analgesics—a review of old and upcoming targets. Br. J. Pharmacol. 180, 975–993 (2023).
Kelly, E., Conibear, A. & Henderson, G. Biased agonism: lessons from studies of opioid receptor agonists. Annu. Rev. Pharmacol. Toxicol. 63, 491–515 (2023).
Volkow, N. D., Michaelides, M. & Baler, R. The neuroscience of drug reward and addiction. Physiol. Rev. 99, 2115–2140 (2019).
Altier, N. & Stewart, J. Dopamine receptor antagonists in the nucleus accumbens attenuate analgesia induced by ventral tegmental area substance P or morphine and by nucleus accumbens amphetamine. J. Pharmacol. Exp. Ther. 285, 208–215 (1998).
Altier, N. & Stewart, J. The role of dopamine in the nucleus accumbens in analgesia. Life Sci. 65, 2269–2287 (1999).
Wood, P. B. Role of central dopamine in pain and analgesia. Expert Rev. Neurother. 8, 781–797 (2008).
Taylor, N. E. et al. The rostromedial tegmental nucleus: a key modulator of pain and opioid analgesia. Pain 160, 2524–2534 (2019).
Wang, X. Q., Mokhtari, T., Zeng, Y. X., Yue, L. P. & Hu, L. The distinct functions of dopaminergic receptors on pain modulation: a narrative review. Neural Plast. 2021, 6682275 (2021).
Kishikawa, Y. et al. Dysregulation of dopamine neurotransmission in the nucleus accumbens in immobilization-induced hypersensitivity. Front. Pharmacol. 13, 988178 (2022).
... continue reading